Light-activated therapy offers new hope for recurrent prostate cancer

NCT ID NCT03067051

Recruiting now Disease control Sponsor: SpectraCure AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment that uses lasers and a light-sensitive drug to destroy cancer cells in the prostate without major surgery. It is for men whose prostate cancer has returned after radiation therapy and who cannot have surgery or more radiation. The goal is to see if the treatment is safe and can clear the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, ON M5G 2M9, Canada
Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust
RECRUITING

London, W1W 7TS, United Kingdom
Skåne University Hospital
RECRUITING

Malmö, Skåne County, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.